UroGen Pharma Financial Statements
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
UroGen Pharma revenue and earnings
In fiscal 2025, UroGen Pharma generated $109.8 million in revenue, up 21.4% from fiscal 2024, its 6th consecutive year of revenue growth. UroGen Pharma reported a net loss of $153.5 million, compared with a loss of $126.9 million a year earlier. Gross margin was 88.7% (down from 90.2%) and operating margin -113.7%.
Over the last 5 fiscal years, URGN's revenue has grown at a 56.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
UroGen Pharma income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.79M | 90.40M | 82.71M | 64.36M | 48.04M | 11.80M | 18.00K | 1.13M | 8.16M | 17.53M |
| Revenue growth (YoY) | +21.45% | +9.29% | +28.52% | +33.96% | +307.17% | +65450.00% | -98.40% | -86.17% | -53.46% | — |
| Cost of Revenue | 12.45M | 8.88M | 9.36M | 7.65M | 5.16M | 1.01M | — | 1.80M | 600.00K | 28.00K |
| Gross Profit | 97.34M | 81.52M | 73.35M | 56.70M | 42.88M | 10.79M | 18.00K | -675.00K | 7.56M | 17.50M |
| Operating Expenses | 222.20M | 178.30M | 138.89M | 135.74M | 135.18M | 137.53M | 109.50M | 76.50M | 27.51M | 16.70M |
| Research & Development | 67.11M | 57.15M | 45.61M | 52.91M | 47.64M | 47.31M | 49.30M | 36.93M | 18.70M | — |
| Selling, General & Admin | 155.10M | 121.15M | 93.27M | 82.84M | 87.53M | 90.22M | 60.20M | — | — | — |
| Operating Income | -124.86M | -96.78M | -65.54M | -79.04M | -92.29M | -126.74M | -109.48M | -77.18M | -19.95M | 798.00K |
| Other Income (Expense) | -670.00K | -229.00K | 838.00K | 72.00K | -153.00K | — | -284.00K | -124.00K | 12.00K | — |
| Pretax Income | -153.42M | -124.04M | -98.32M | -108.03M | -109.37M | -125.11M | -105.15M | -75.53M | -19.98M | -1.94M |
| Income Tax | 78.00K | 2.83M | 3.92M | 1.75M | 1.45M | 3.37M | — | 125.00K | 19.00K | — |
| Net Income | -153.49M | -126.87M | -102.24M | -109.78M | -110.82M | -128.48M | -105.15M | -75.66M | -20.00M | -1.94M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 | -5.90 | -5.12 | -4.80 | -2.14 | -1.91 |
| EPS (Diluted) | — | — | — | — | -4.96 | -5.90 | -5.12 | -4.80 | -2.14 | -1.91 |
| Shares Outstanding (Basic) | 48.12M | 42.88M | 28.83M | 22.81M | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 2.31M |
| Shares Outstanding (Diluted) | — | — | — | — | 22.35M | 21.78M | 20.53M | 15.75M | 9.72M | 2.31M |
| EBITDA | -124.56M | -96.45M | -64.73M | -78.12M | -91.46M | -126.32M | -109.18M | -76.78M | -19.75M | 998.00K |
| Gross Margin | 88.66% | 90.18% | 88.68% | 88.11% | 89.27% | 91.45% | 100.00% | -59.84% | 92.65% | 99.84% |
| Operating Margin | -113.73% | -107.06% | -79.23% | -122.82% | -192.11% | -1074.15% | -608211.11% | -6842.20% | -244.55% | 4.55% |
| Net Margin | -139.81% | -140.35% | -123.61% | -170.58% | -230.67% | -1088.94% | -584144.44% | -6707.18% | -245.16% | -11.07% |
This table shows 10 annual periods of UroGen Pharma's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow URGN's reporting calendar. What is a income statement?